N@N

ALAMEDA, Calif.--([ BUSINESS WIRE ])--InSite Vision Incorporated (OTCBB:INSV) will hold its Annual Meeting of Stockholders at 10:00 a.m. Pacific Time on Thursday, May 31, 2012 at the company's headquarters at 965 Atlantic Avenue, Alameda, California. Company management will host a webcast of the meeting beginning at 10:00 a.m. PDT/1:00 p.m. EDT which will be available on the Investor Relations page of the company's website ([ www.insitevision.com ]). For those who miss the live broadcast, an archived replay will be available shortly thereafter.

Analysts and investors can participate in the Annual Meeting via conference call by dialing 888-713-4216 for domestic callers and 617-213-4868 for international callers and entering the pass code 91786574. A telephone replay will be available following the conclusion of the meeting for two weeks by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers with the pass code 88309016.

About InSite Vision

InSite Vision is advancing new and superior ophthalmologic products for unmet eye care needs. The companyas product portfolio utilizes its proven DuraSite bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Visionas clinical-stage ophthalmic product pipeline includes AzaSite Plus^a" and DexaSite^a" for the treatment of eye infections, BromSite^a" for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit [ www.insitevision.com ].